With a strong track record across APAC, Francis Wan’s appointment marks a powerful acceleration of Medison’s growth in the region

ZUG, Switzerland, Oct. 23, 2025 /PRNewswire/ — Medison, the creator of a first-of-its-kind unified global commercialization platform for breakthrough therapies, today announced the appointment of Francis Wan as VP, GM Asia Pacific (APAC) and member of the company’s Global Leadership Team.

From left to right: Meir Jakobsohn, Executive Chairman Medison, Francis Wan, VP GM APAC,Victor Papamoniodis, Chief Commercial Officer, Gil Gurfinkel, CEO

Francis will lead Medison’s strategy and operations across the APAC region, a critical growth area for the company’s platform. With more than 20 years of biopharmaceutical leadership experience, including serving as President Asia Pacific at Biogen and Managing Director of Commercial Operations at MSD China, he has successfully scaled organizations, advanced innovative therapies, and built sustainable access models across diverse APAC markets. His expertise in rare disease and oncology, together with his extensive experience in China’s healthcare landscape, adds a vital dimension to Medison’s strategy for the region.

“Across APAC, breakthrough therapies are still out of reach for many patients, leaving a vast and diverse population with significant unmet needs,” said Francis Wan. “Through Medison’s global commercialization platform, we have a unique opportunity to change this reality and expand access to breakthrough therapies. Having spent much of my career in China and across APAC, I understand firsthand how essential it is to deliver sustainable solutions and enable faster access for patients with rare and severe diseases.”

“Medison was founded on the belief that every patient, no matter where they live, deserves timely access to breakthrough therapies,” said Meir Jakobsohn, Founder and Executive Chairman of Medison. “Francis’s appointment reflects our continued investment in APAC and marks an important step in accelerating additional growth in the region, a region with enormous need and opportunity.”

“Francis joining Medison is another important milestone in our global growth journey,” said Gil Gurfinkel, CEO of Medison. “With his appointment, we continue to advance toward completing our expansion roadmap and building a world leader and the best commercialization company for international markets. Francis’s extensive experience with healthcare systems and his proven record of creating access and commercial success in China and across APAC will strengthen our ability to accelerate access to life-changing therapies and deepen our partnerships in the region and on a global scale.”

“Francis brings outstanding expertise and a proven track record in establishing and scaling biopharma operations in China and the broader APAC region,” said Victor Papamoniodis, Chief Commercial Officer at Medison. “His leadership will be instrumental in scaling our platform and expanding patient access to breakthrough therapies in APAC.”

About Medison
At Medison, we are addressing one of the pharma industry’s most pressing challenges: enabling access to breakthrough therapies for patients with severe and rare diseases in international markets where traditional commercialization models fall short. 

As the creator and leader of the global partnership category, we have built a first-of-its-kind unified commercialization platform that enables biotechs to effectively plan, optimize and launch their therapies on a global scale. 

With a strong leadership team and a proven track record, we are the partner of choice for innovative biotech companies seeking to expand beyond the US, Western Europe and Japan into regions where most of the world’s population resides. Our affiliate-like model integrates commercial, medical and operational capabilities across diverse geographies, accelerating access and delivering life-changing treatments to more patients, faster. 

Medison is on a mission to ensure that every patient, regardless of where they live, has the opportunity to benefit from breakthrough therapies. 

For more information, please visit https://www.medisonpharma.com/

Contact:
Margo Corn Ladani 
Senior Manager, Global Communications 
T:  +972 52 6606710
E: MargoC@medisonpharma.com

• Prestigious peer-review validates HCB101’s differentiated mechanism and translational strength.
• Clinical data show a nearly 90% partial response rate in 2L gastric cancer (combo) and safe escalation to 30 mg/kg (mono)

TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ — HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced that its manuscript describing the discovery and preclinical development of HCB101, an engineered SIRPα-Fc fusion protein, has been published in the Journal of Hematology & Oncology (SCI Impact Factor 40.4; for reference, leading journals in the field of immuno-oncology include Journal of Clinical Oncology (impact factor 41.9), The Lancet Oncology (35.9), and Nature Cancer (28.5)).

The publication, titled “HCB101: A Novel Potent Ligand-Trap Fc-fusion Protein Targeting the CD47-SIRPα Pathway with High Safety and Preclinical Efficacy for Hematological and Solid Tumors,” describes the rational protein engineering that enabled HCB101 to restore macrophage-mediated phagocytosis and bridge innate and adaptive immune responses while reducing red blood cell binding. In preclinical studies, HCB101 showed broad activity across more than 80 xenograft and PDX tumor animal models with a safety profile that differs from first- and second-generation CD47-targeting agents.

Notably, a US competitor focusing on CD47/SIRPα published findings in JHO in November 2020, reporting on a third-generation anti-CD47–SIRPα therapy. This underscores the journal’s strong recognition within the field. The continued publication of anti-CD47 biologics in JHO highlights both the scientific importance of ongoing advancements and the journal’s role as a leading international platform for preclinical and translational research on anti-CD47 therapies.

“Publication in the Journal of Hematology & Oncology affirms the scientific rigor and innovation behind HCB101 and emphasizes its differentiated preclinical foundation,” said Scott Liu, PhD, Chairman, CEO, and Founder of HanchorBio. “Importantly, these insights are being directly translated into clinical studies: combined with standard-of-care, HCB101 has demonstrated a clear dose-dependent efficacy profile in 2L gastric cancer, culminating in a nearly 90% partial response rate at 5.12 and 8.0 mg/kg. In parallel, we have now escalated monotherapy dosing to 30 mg/kg without safety concerns. These milestones highlight HCB101’s potential to serve as a backbone immunotherapy across solid tumors and hematologic malignancies and lay the groundwork for expanding into autoimmune indications where CD47-SIRPα biology is also potentially useful in creating a new B-cell depletion therapy.”

Clinical Progress Strengthens Differentiated Best-in-Class Profile
HCB101 is currently being evaluated in multinational Phase 1 and Phase 1b/2a trials:

• Monotherapy (HCB101-101, NCT05892718):
  The Safety Review Committee (SRC) has reviewed the safety data up to 30 mg/kg weekly and found no dose-limiting toxicities, confirming a wide therapeutic window. Early signs of efficacy included two confirmed partial responses (PRs) in head and neck squamous cell carcinoma and marginal zone lymphoma, along with stable disease (SD) in nine patients, including over 40 weeks of disease control in platinum-resistant ovarian cancer.

• Combination (HCB101-201, NCT06771622):
  In the triplet regimen for 2L-gastric cancer (HCB101 + ramucirumab + paclitaxel), emerging activity was first observed at 2.56 mg/kg, where evaluable patients achieved SD with modest tumor shrinkage, averaging a 6% reduction in tumor size in the dose cohort. At 5.12 mg/kg, all three evaluable patients achieved confirmed PRs (33%–46% tumor reductions). At 8.0 mg/kg, all three evaluable patients have now achieved confirmed PRs (tumor shrinkage up to -78%) after extended follow-up. Together, these results represent a nearly 90% confirmed response rate (6 of 7 patients) at ≥ 5.12 mg/kg dose level — a striking outcome in a setting where the typical overall response rate (ORR) for the SOC is only 26.5%.

“The data now published in JHO validate the design strategy that made HCB101 possible – balancing high efficacy with a clean safety margin where earlier CD47-targeting agents failed,” added Wenwu Zhai, PhD, Chief Scientific Officer of HanchorBio. “Seeing those preclinical insights translate into durable monotherapy activity and remarkable combination dose-dependent responses in gastric cancer provides confidence not only for oncology but also for new areas such as autoimmunity. HCB101’s differentiated mechanism and safety profile open the door to rational combinations and next-generation applications well beyond cancer.”

About HCB101: A Differentiated CD47-SIPRα Blockade
HCB101 is a 3.5^th-generation, affinity-optimized SIRPα-Fc fusion protein with intact IgG4 effector function, developed using HanchorBio’s proprietary FBDB™ platform. Engineered for selective CD47 blinding on tumors with low affinity for red blood cells, HCB101 avoids the hematologic toxicities commonly associated with anti-CD47 monoclonal antibodies, while preserving strong antibody-dependent cellular phagocytosis (ADCP) and innate-to-adaptive immune bridging.

Key Differentiators of HCB101:

• Enhanced safety: Low RBC binding minimizes anemia and thrombocytopenia risk.
• Robust immune activation: Engineered to enhance ADCP and innate-to-adaptive bridging.
• Broad tumor applicability: Demonstrated activity in >80 PDX/CDX preclinical models.
• Clinical translation: Early efficacy as monotherapy with durable disease control, and 100% ORR and disease control rate (DCR) at the middle dose cohort in combination with standard-of-care for 2L-gastric cancer.

About HanchorBio

Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx), a global biotechnology company specializing in immuno-oncology, is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and international development, aiming to rewrite cancer therapies. Committed to reactivating the immune system to fight diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables the development of unique biologics with diverse multi-targeting modalities, unleashing both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs. For more information, please visit: www.HanchorBio.com

SHANGHAI, Oct. 23, 2025 /PRNewswire/ — Today, JCET Group (SSE: 600584), a leading global provider of integrated circuit (IC) back-end manufacturing and technology services, released its financial results for the third quarter of 2025. JCET reported record Q3 revenue of RMB 10.06 billion, up 8.6% quarter-on-quarter, marking the highest third-quarter revenue in the company’s history. Net profit attributable to shareholders reached RMB 480 million, an increase of 80.6% from the previous quarter, while profit before tax (PBT) was up 29.3% year-on-year to RMB 610 million.

For the first nine months of 2025, JCET generated RMB 28.67 billion in revenue, up 14.8% year-on-year, setting a new record for the same period. Net profit attributable to shareholders totaled RMB 950 million.

In 2025, JCET accelerated efforts to upgrade advanced packaging capabilities and expand production capacity, while driving application-focused innovation and strengthening both global and local customer engagement. As a result, capacity utilization rose steadily from Q1 to Q3, reaching near-full levels across key product lines, including wafer-level packaging, power device packaging, and power management chip packaging.

Several business segments delivered strong year-on-year revenue growth in Q3 YTD 2025. Revenue from computing electronics, industrial and medical electronics, and automotive electronics rose by 69.5%, 40.7% and 31.3%, respectively. JCET’s transformation continues to be driven by investment in high value-added areas, new product ramp-ups, and the expansion of mass production. With demand rebounding and utilization rates rising, the company plans to further optimize its product mix, prioritize capacity for high-margin products, and enhance overall profitability.

In the first three quarters of 2025, JCET significantly increased its R&D investment, with expenses rising 24.7% year-on-year to RMB 1.54 billion. The company achieved breakthrough progress in several critical technology areas, including co-packaged optics (CPO), glass substrates, large-format fcBGA packaging, and high-density system-in-package (SiP) solutions. In parallel, JCET continues to attract top global talent and strengthen its R&D capabilities, further solidifying the foundation for long-term innovation and sustainable growth.

For more information, please refer to the JCET Q3 2025 Report. 

About JCET Group

JCET Group is a global leader in integrated circuit back-end manufacturing and technology services. We provide comprehensive turnkey solutions, including semiconductor package integration design, wafer probing, bumping, assembly, final testing, and global drop shipments.

Utilizing advanced wafer-level packaging, 2.5D/3D packaging, System-in-Package solutions, and reliable flip chip and wire bonding technologies, we support a wide range of applications, including automotive, artificial intelligence, high-performance computing, storage, communication, smart devices, industrial and medical sectors, and power and energy. With cutting-edge R&D centers in China and Korea, and manufacturing facilities across China, Korea, and Singapore, we deliver efficient supply chain solutions and maintain close collaboration with our global customers.

Engineers to oversee tech transfers, support manufacturing partnerships, and co-develop AI-driven solutions with customers

SINGAPORE, Oct. 23, 2025 /PRNewswire/ — Switzerland’s Enclustra GmbH today launched Enclustra Asia, its regional headquarters in Singapore, marking a strategic expansion into Southeast Asia’s advanced manufacturing and innovation landscape with an eye to talent acquisition.

The new Asian HQ will recruit about 100 design engineers, sales, and marketing professionals to oversee technology transfers from Enclustra’s Zurich headquarters, coordinate partnerships with local manufacturers, and collaborate closely with customers to deliver next-generation AI-enabled solutions tailored for commercial applications.

Recently, the Swiss Tech Company, a global leader in field-programmable gate array (FPGA) solutions, launched its new Physical AI-Machine Learning Technology Line in collaboration with SiMa.ai.

The Singapore-based engineers will play a key role in localising Enclustra’s FPGA-based technologies, adapting high-performance computing platforms for regional needs, and accelerating product development cycles. Their work will also support joint innovation initiatives with academic and industry partners, reinforcing Singapore’s position as a hub for deep-tech talent and smart manufacturing.

This talent acquisition is intended to support the estimated US$100 million in contracts that Enclustra plans to outsource annually to Singapore’s manufacturing ecosystem within the next three to four years.

The key thrusts of Enclustra’s strategic moves are:

• Establishment of Enclustra Asia, with Singapore designated as its Operations Centre of Excellence. The new entity will serve as a hub for sales, engineering services, regional manufacturing, and the design and development of FPGA-based solutions.
• Collaboration with Singapore universities with a view to setting up innovation labs. Discussions are currently underway with the Nanyang Technological University (NTU) to launch several projects.
• Design transfer coordination from Enclustra’s global headquarters in Zurich to appointed contract manufacturers in Singapore. These partnerships are expected to contribute approximately US$100 million annually to Singapore’s export ecosystem by FY2026, with a projected compound annual growth rate of 40% thereafter.

Enclustra planned for its Asia Pacific expansion in 2020 as part of its five-year roadmap. Following the setting up of its US Office in San Diego in 2023, plans were underway for the Singapore operations. A key driving force behind the choice of Singapore is its strong pool of FPGA engineering talent, particularly in sectors such as semiconductors, embedded systems, and advanced manufacturing.

Enclustra CEO Phillip Bächtold said, “Enclustra’s purpose has always been clear: to enable innovation that is life-saving, life-changing, and dream-making in terms of the impact on human lives. Our FPGA technology empowers customers to shape the future, whether that means developing smarter medical devices, enhancing safer autonomous systems, or achieving faster and more efficient industrial control.

Our expansion to Singapore and collaboration with Singapore universities mark the next step in that journey. It’s about putting the full power of reconfigurable computing closer to our customers, so they can move from concept to breakthrough faster than ever. We’re not just advancing hardware; we’re enabling the ideas that define tomorrow.”

Economic Development Board Executive Vice President Ms Cindy Koh said, “Singapore offers a vibrant, advanced manufacturing ecosystem for global companies looking to expand into Asia and scale innovative solutions to international markets. Enclustra’s latest investment brings new FPGA-based solutions that will strengthen Singapore’s advanced manufacturing sector, creating more partnership opportunities for our local enterprises and adding 100 skilled roles here.”

Switzerland’s Ambassador to Singapore, H.E. Mr Frank Grütter, who was present at the event, said: “Enclustra’s investment is more than just an expansion – it also strengthens the partnership between Switzerland and Singapore.

“I am convinced that it will accelerate the development of the advanced electronics sector in this region and reinforce Switzerland’s reputation for precision, reliability and innovation – characteristics that we share with Singapore,” he said.

About Enclustra GmbH

Enclustra is an innovative, dynamic, and growing company specialising in FPGA design, with headquarters in Zurich, Switzerland, and subsidiaries in Germany, France, the USA, and China. As a leader in FPGA design and development, Enclustra offers a product portfolio of FPGA-based electronic modules and FPGA-optimised IP solutions for industrial customers and R&D organisations. In parallel, Enclustra provides leading engineering services in FPGA system design, covering the entire spectrum of FPGA-based system development, from high-speed hardware and HDL firmware to embedded software, as well as from system design, specification, and implementation to prototyping. Leveraging our expertise in cutting-edge FPGA technology and diverse application knowledge, Enclustra delivers high-performance solutions across various industries, minimising development effort and accelerating your time-to-market.

PROVIDENCIALES, Turks and Caicos Islands, Oct. 23, 2025 /PRNewswire/ — KuCoin, a leading global crypto platform built on trust, today announced the launch of KuPool, a state-of-the-art mining pool service designed to synergize with KuMining and the KuCoin exchange. Led by mining veteran Chris Zhu (Zhu Fa), this strategic alignment establishes a comprehensive, closed-loop ecosystem that connects hashrate generation, mining, and asset management—offering users an efficient and secure mining experience within KuCoin’s ecosystem. Chris Zhu, former co-founder of BTC.com and Poolin, brings over a decade of experience in global mining, reinforcing the platform’s credibility.

In line with KuCoin’s refreshed brand vision, “Trust First. Trade Next.”, KuPool places verifiable hashrate at the center of its framework. KuPool constructs a transparent mining system from technological, operational, and philosophical perspectives—earning the trust of global miners. The platform features an efficient, low-latency, and traceable profit-sharing mechanism that ensures fair and verifiable distribution. It currently supports mainstream and merged mining cryptocurrencies such as LTC, DOGE, PEPE, Lucky, and BELLS, with BTC mining to launch soon, further enriching the ecosystem. By leveraging transparent and secure hashrate verification, KuPool establishes verifiable hashrate as a trust asset, fully embodying its philosophy: Verified Hashing, Trusted Mining.

Backed by KuCoin’s extensive resources—including its proven record in secure asset management and regulatory compliance—KuPool incorporates multi-layered encryption, real-time monitoring, and rigorous operational safeguards, reflecting KuCoin’s ethos that “Trust Is the Currency We Trade In.”

“KuPool not only inherits the technical excellence and professional advantages of traditional mining pools but also redefines the mining industry’s structure through transparent, compliant, and financialized operations,” said Chris Zhu, Head of KuPool. “With KuCoin’s global ecosystem and our team’s extensive experience, we are committed to delivering cutting-edge mining services and verifiable, trusted returns.”

“The launch of KuPool extends the KuCoin ecosystem blueprint, connecting KuCoin, KuMining, and KuPool to forge a new paradigm of hashrate finance,” BC Wong, CEO of KuCoin, added. “This integration transforms KuCoin from a traditional asset trading platform into a comprehensive hashrate production and allocation hub, driving the industry into a new era of real yields and trust-based mining.”

About KuPool

KuPool is a new mining pool service within the KuCoin ecosystem, dedicated to building transparent, secure, and verifiable mining infrastructure. Leveraging KuCoin’s advantages in security, compliance, and asset management, KuPool offers miners a fair and trusted experience through efficient, traceable profit-sharing mechanisms and support for major and merged mining cryptocurrencies such as LTC, DOGE, PEPE, Lucky, and BELLS. With “Verified Hashing, Trusted Mining” at its core, KuPool promotes the sustainable growth of the blockchain hashrate economy.

Learn More: https://www.kupool.com/

PROVIDENCIALES, Turks and Caicos Islands, Oct. 23, 2025 /PRNewswire/ — KuCoin, a leading global crypto platform built on trust, today announced the launch of KuPool, a state-of-the-art mining pool service designed to synergize with KuMining and the KuCoin exchange. Led by mining veteran Chris Zhu (Zhu Fa), this strategic alignment establishes a comprehensive, closed-loop ecosystem that connects hashrate generation, mining, and asset management—offering users an efficient and secure mining experience within KuCoin’s ecosystem. Chris Zhu, former co-founder of BTC.com and Poolin, brings over a decade of experience in global mining, reinforcing the platform’s credibility.

In line with KuCoin’s refreshed brand vision, “Trust First. Trade Next.”, KuPool places verifiable hashrate at the center of its framework. KuPool constructs a transparent mining system from technological, operational, and philosophical perspectives—earning the trust of global miners. The platform features an efficient, low-latency, and traceable profit-sharing mechanism that ensures fair and verifiable distribution. It currently supports mainstream and merged mining cryptocurrencies such as LTC, DOGE, PEPE, Lucky, and BELLS, with BTC mining to launch soon, further enriching the ecosystem. By leveraging transparent and secure hashrate verification, KuPool establishes verifiable hashrate as a trust asset, fully embodying its philosophy: Verified Hashing, Trusted Mining.

Backed by KuCoin’s extensive resources—including its proven record in secure asset management and regulatory compliance—KuPool incorporates multi-layered encryption, real-time monitoring, and rigorous operational safeguards, reflecting KuCoin’s ethos that “Trust Is the Currency We Trade In.”

“KuPool not only inherits the technical excellence and professional advantages of traditional mining pools but also redefines the mining industry’s structure through transparent, compliant, and financialized operations,” said Chris Zhu, Head of KuPool. “With KuCoin’s global ecosystem and our team’s extensive experience, we are committed to delivering cutting-edge mining services and verifiable, trusted returns.”

“The launch of KuPool extends the KuCoin ecosystem blueprint, connecting KuCoin, KuMining, and KuPool to forge a new paradigm of hashrate finance,” BC Wong, CEO of KuCoin, added. “This integration transforms KuCoin from a traditional asset trading platform into a comprehensive hashrate production and allocation hub, driving the industry into a new era of real yields and trust-based mining.”

About KuPool

KuPool is a new mining pool service within the KuCoin ecosystem, dedicated to building transparent, secure, and verifiable mining infrastructure. Leveraging KuCoin’s advantages in security, compliance, and asset management, KuPool offers miners a fair and trusted experience through efficient, traceable profit-sharing mechanisms and support for major and merged mining cryptocurrencies such as LTC, DOGE, PEPE, Lucky, and BELLS. With “Verified Hashing, Trusted Mining” at its core, KuPool promotes the sustainable growth of the blockchain hashrate economy.

Q3 2025 Key Highlights

• According to CoinGecko’s Q3 Crypto Industry Report, the total quarterly perpetual trading volume across all centralized exchanges (CEX) hit an all-time high, with BingX ranked amongst the top performers.
• Copy trading saw a cumulative trading volume of over $80 billion, with total copy orders exceeding 700 million as of Q3 2025.
• BingX AI surpassed 3 million early users in Q3, collectively resolving over 30 million queries across BingX AI Bingo and BingX AI Master.
• BingX achieved both PCI DSS 4.0.1 and ISO 27001 certification in Q3, highlighting its dedication to information and payments security for all users across the platform.
• BingX VIP underwent a comprehensive upgrade, introducing exclusive benefits such as discounted fiat exchange rates, zero-fee guaranteed price orders, and zero slippage for trigger orders.
• BingX Academy 2.0 launched in Q3, featuring an intuitive interface, expanded tutorials, and AI-powered learning pathways to empower global Web3 and crypto learners.

PANAMA CITY, Oct. 23, 2025 /PRNewswire/ — BingX, a leading cryptocurrency exchange and Web3 AI company,  today released its Q3 2025 recap, highlighting sustained growth across AI innovation, security, product development, and global engagement. The quarter showcased BingX’s continued progress in integrating technology, trust, and community — driving forward its mission to make trading more intelligent, inclusive, and accessible.

According to CoinGecko’s Q3 Crypto Industry Report, total CEX perpetual futures trading volumes reached an all-time high during the quarter. BingX recorded continued strong quarter-to-quarter growth, highlighting its increasing market share and growing recognition as a leading global derivatives platform.

In Q3, BingX strengthened its global compliance framework by achieving both ISO 27001 and PCI DSS v4.0.1 certifications — two of the most recognized international standards for information and payment security. These accreditations affirm BingX’s commitment to safeguarding user data, ensuring secure transactions, and maintaining robust operational integrity across its platform.

BingX Copy Trading continued to display strong performance, featuring over 40,000 elite traders and surpassing 700 million recorded copy orders as of Q3, with a cumulative trading volume exceeding $80 billion. Meanwhile, professional traders benefited from one of the industry’s most rewarding programs, earning up to 32% in commissions, along with fixed base salaries, tailored onboarding, and growth tools supported by BingX’s multi-million-dollar Copy Trader Program.

BingX AI reached 3 million early users in Q3, collectively resolving over 30 million user issues through its growing product lineup, including BingX AI Bingo and BingX AI Master. These products exemplify BingX’s vision for adaptive, data-driven trading — offering real-time insights, personalized strategies, and intelligent assistance that evolves with market dynamics. As AI becomes central to user experience, BingX continues to redefine how traders learn, analyze, and execute, making intelligent finance accessible to a global audience.

BingX VIP underwent a comprehensive upgrade, introducing exclusive benefits such as discounted fiat exchange rates, zero-fee guaranteed price orders, zero slippage for trigger orders, liquidation insurance, and a 13% APR wealth management product for first-time VIPs. Each member is also paired with a dedicated relationship manager offering one-on-one concierge-style support — combining personalized service with elite trading privileges.

In line with its commitment to education, BingX Academy 2.0 unveiled a major upgrade, now featuring an intuitive interface, expanded tutorials, and AI-powered learning pathways. Covering topics from product guides and trading strategies to DeFi, Web3, and risk management, the new Academy equips users with structured, interactive learning experiences that empower financial confidence and responsible participation in digital markets.

“Q3 marked a period of real progress for BingX, not just in product innovation, but in purpose,” said Vivien Lin, Chief Product Officer at BingX. “We advanced AI adoption, improved trading transparency, and launched tools that empower users to grow confidently. Whether through education, innovation, or community, our focus remains clear: to make digital finance more intelligent, more human-centered, and more connected to real-world value.”

About BingX

Founded in 2018, BingX is a leading crypto exchange and Web3 AI company, serving a global community of over 20 million users. With a comprehensive suite of AI-powered products and services, including derivatives, spot trading, and copy trading, BingX caters to the evolving needs of users across all experience levels, from beginners to professionals. Committed to building a trustworthy and intelligent trading platform, BingX empowers users with innovative tools designed to enhance performance and confidence. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports sponsorship.

For more information, please visit: https://bingx.com/